Right Patient, Right Treatment, Right Time: Utilizing Early, High-Efficacy Therapies to Improve Outcomes in RRMS


Fred D. Lublin, MD, FAAN, FANA
Saunders Family Professor of Neurology
Director, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Icahn School of Medicine at Mount Sinai, New York, NY
Fred D. Lublin, MD, FAAN, FANA

Fred D. Lublin, MD is the Saunders Family Professor of Neurology at The Icahn School of Medicine at Mount Sinai and Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at that institution.

Dr. Lublin received his medical degree in 1972 from Jefferson Medical College, Philadelphia, PA. He completed his internship in Internal Medicine from the Bronx Municipal Hospital, Albert Einstein Medical Center, and his residency at the New York Hospital, Cornell Medical Center.

As a neuroimmunologist, Dr. Lublin has a special interest in immune functions and abnormalities affecting the nervous system. He has been involved in both basic science and clinical research. He and his colleagues were among the first in the country involved with studies of Interferon beta-1b, which was approved by the Food & Drug Administration in 1993 to treat the relapsing-remitting form of Multiple Sclerosis. He is currently involved with several new clinical research protocols on promising agents for treating various aspects of MS. He was chairman of the National MS Society (USA) advisory committee on clinical trials of new drugs in Multiple Sclerosis and the National Multiple Sclerosis Society’s Research Programs Advisory Committee. He was a member of the National MS Society National Board of Directors. He is past Chair of the New York City/Southern New York Chapter of NMSS Clinical Advisory Committee. He is a member of the International Medical & Scientific Board of the Multiple Sclerosis International Federation. Dr. Lublin and his colleagues at the National MS Society have re-defined the clinical course definitions of MS, updated in 2014. He has chaired a task force on the ethics of placebo-controlled trials in MS. Dr. Lublin is a member of the international panel that periodically redefines the diagnostic criteria for MS (McDonald Criteria). Dr. Lublin is co-chair of the National Institute of Neurological Diseases and Stroke MS Common Data Element committee and a member of their steering committee. He is a member of the WHO Advisory Group for the Revision of ICD-10 Diseases of the Nervous System working group on demyelinating diseases of the central nervous system. He was a Co-Chief and founding Editor of the journal Multiple Sclerosis and Related Disorders.

Dr. Lublin has published numerous scientific articles and is a member of many professional societies and advisory boards. Dr. Lublin has served as a consultant to the National Institutes of Health and to many pharmaceutical/biotech companies in all phases of new drug development and in preparation for presentation to the FDA and their advisory panels. He was the Principal Investigator of the NIH-sponsored multicenter Combination Therapy study in Multiple Sclerosis. In June of 2019, Dr. Lublin was awarded the June Halper Lifetime Achievement Award from the Consortium of Multiple Sclerosis Centers.

Anne H. Cross, MD
Professor of Neurology, Manny and Rosalyn Rosenthal and Dr. John L. Trotter Multiple Sclerosis
Center Chair in Neuroimmunology, Washington University School of Medicine, St. Louis, MO
Anne H. Cross, MD

Dr. Anne H. Cross is a professor of Neurology at Washington University in St. Louis, where she holds the Manny & Rosalyn Rosenthal and Dr. John L. Trotter MS Center Chair in Neuroimmunology and has served as Section Head of the Neuroimmunology/MS Section since 2001.

Raised in Mobile, Alabama, Dr. Cross graduated cum laude from the University of Alabama School of Medicine and was selected for the Alpha Omega Alpha medical honorary. After residency training in adult neurology at George Washington University, she spent several years as a post-doctoral fellow training in neuroimmunology and neuropathology at the National Institute of Health with Drs. Dale McFarlin and Henry McFarland and later at Albert Einstein College of Medicine with Drs. Cedric Raine and Celia Brosnan. Dr.Cross pursued further training in the clinical care of MS patients at Albert Einstein College of Medicine with Dr. Labe Scheinberg and received the Harry Weaver Neuroscience Scholar award of the National Multiple Sclerosis Society in 1990 and the John Jay Dystel Prize in 2019.

Dr. Cross joined the Washington University Department of Neurology in 1991. Her research has been continually funded by the National MS Society, the NIH and/or the U.S. Department of Defense since she opened her laboratory in 1991. Her laboratory currently focuses on advanced imaging studies of progressive MS and the role(s) of B cells and B cell products in MS and its animal models. During her nearly 30 years at Washington University, she has trained more than 30 students, residents, and fellows; she is very proud that they all continue to actively contribute to the research and care of MS and related diseases.

Joseph R. Berger, MD, FACP, FAAN, FANA
Professor of Neurology
Associate Chief, Multiple Sclerosis Division
Perelman School of Medicine, University of Pennsylvania Philadelphia, PA
Joseph R. Berger, MD, FACP, FAAN, FANA

Joseph R. Berger, MD, FACP, FAAN, FANA, is Professor of Neurology and Associate Chief of the Multiple Sclerosis Division of the Department of Neurology at the Perelman School of Medicine at the University of Pennsylvania in Philadelphia. Dr. Berger is a summa cum laude graduate of the Pennsylvania State University – Jefferson Medical College 5 Year Accelerated Medical Program and a member of the national medical honor society, Alpha Omega Alpha. He completed his residency in internal medicine at Georgetown University Hospital and his neurology residency at the University of Miami School of Medicine and is board certified in both internal medicine and neurology. In 1981, he joined the faculty of the University of Miami School of Medicine serving in both the Departments of Neurology and Internal Medicine. At that institution, he held the Whigham-Berger Endowed Chair for the study of neurological complications of HIV/AIDS, the first endowed chair for the study of the neurological complications of HIV/AIDS. From 1995 through 2013, Dr. Berger was the Chairman of the Department of Neurology at the University of Kentucky where he was the Ruth L. Works Professor of Neurology and director of the UK Multiple Sclerosis Clinic.

He is a Fellow of the American College of Physicians, American Academy of Neurology, and the American Neurological Association (ANA). In 2014 he was the recipient of the Pioneer Award from the International Society of Neurovirology and gave the prestigious Raymond D. Adams Lecture at the annual meeting of the ANA. In 2015 he was awarded the Distinguished Teaching Award from the ANA. In 2018, he received the Annual Alumni Achievement Award from the Sidney Kimmel Medical College, Thomas Jefferson University. His research interests include progressive multifocal leukoencephalopathy, the neurological complications of HIV/AIDS, multiple sclerosis, and other inflammatory disorders of the brain. He has published more than 250 refereed papers, more than 100 chapters, and has co-edited three textbooks (Berger JR and Levy RM: AIDS and the Nervous System, 2nd edition, Raven Press, New York, 1996; Nath A, Berger JR: Clinical Neurovirology, Marcel Dekker, New York, 2003 (2nd edition forthcoming in 2019); Portegies P, Berger JR: HIV/AIDS and the Nervous System, Elsevier, Amsterdam, 2007). Dr. Berger co- founded and chaired the first international conference on the neurological complications of HIV, the Neuroscience of HIV meeting. He also established the Commonwealth Neurological Society for neurologists in the state of Kentucky. Dr. Berger has a longstanding interest in international health and was one of the founding members of People-to-People, an organization for HIV/AIDS care and education in East Africa.

Statement of Need

Recent studies have demonstrated the benefits of early and aggressive treatment strategies in reducing disability progression and the frequency of relapses in patients with relapsing remitting multiple sclerosis (RRMS), marking a paradigm shift in the treatment of patients with RRMS. The traditional escalation approach is now often set aside in favor of the more individualized “induction” approach, which utilizes “early and aggressive” treatment with high-efficacy disease-modifying therapies (DMTs) to treat patients with high-risk disease.

The induction approach requires selection of DMTs based on disease activity, prognostic factors, and patient characteristics. This is challenging for clinicians due to the expanding treatment landscape for RRMS and the lack of specific guidelines. Additionally, neurologists often lack the knowledge and competence to identify patients who are candidates for this approach.

In this CME Outfitters virtual symposium, expert faculty will focus on the prognostic factors that should be considered when developing treatment plans for patients with MS, as well as the latest clinical data on approved and emerging DMTs, so that clinicians can confidently develop tailored treatment approaches based on individual patient characteristics and appropriately monitor treatment response, safety, and tolerability.

Learning Objectives

At the end of this CME/CE activity, participants should be able to:

  • Select patients with RRMS who are likely to benefit from early treatment with high-efficacy DMTs.
  • Develop tailored treatment approaches based on individual patient characteristics.
  • Apply the latest clinical data on approved and emerging DMTs in monitoring treatment response, safety, and tolerability.

The following learning objectives pertain only to those requesting CNE or CPE credit:

  • Describe patients with RRMS who are likely to benefit from early treatment with high-efficacy DMTs.
  • Summarize a tailored treatment approach based on individual patient characteristics.
  • Explain the latest clinical data on approved and emerging DMTs in monitoring treatment response, safety, and tolerability.

Financial Support

Supported by educational grants from Celgene Corporation, a Bristol Myers Squibb company and from Genentech, a member of the Roche Group.

Target Audience

Neurologists, MS specialists, PAs, nurse practitioners, nurses, and pharmacists

Credit Information

Physicians (ACCME) 1.0

CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note to Nurse Practitioners

Nurse Practitioners can apply for AMA PRA Category 1 Credit through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit  from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Pharmacists/Pharmacy Tech (ACPE) 1.0

This application-based activity is approved for 1.0 contact hour (0.10 CEUs) of continuing pharmacy credit.
Activity UAN: JA0007185-0000-21-160-H01-P


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.


ABPN Diplomates may select any CME activity relevant to their practice to count towards ABPN MOC requirements.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr.Lublin reports that he receives research support from Actelion Pharmaceuticals; Biogen; Brainstorm Cell Therapeutics Inc; National Institutes of Health (NIH); National Multiple Sclerosis Society (NMSS); Novartis; and Sanofi. He has consulting agreements, serves on advisory boards, or Data and Safety Monitoring Board for Acorda Therapeutics; Actelion Pharmaceuticals/Janssen Pharmaceuticals, Inc.; Apitope; Brainstorm Cell Therapeutics Inc.; Atara Biotherapeutics, Inc.;Avotres; Biogen; EMD Serono, Inc; GW Pharmaceuticals; Immunic, Inc.; Innate Immunotherapeutics; Jazz Pharmaceuticals, Inc.; Mapi Pharma; MedDay Pharmaceuticals; MedImmune/ Viela Bio; Mylan; Novartis; Orion Biotechnology; Polpharma; Receptos, Inc./Celgene Corporation; Roche/Genentech, Inc.; Sanofi/Genzyme Corporation; Teva Pharmaceuticals; The Population Council, Inc. and TG Therapeutics. He is a speaker for Sanofi (non-promotional).

Dr. Berger reports he received research support from Biogen and Genentech, Inc. He serves on the advisory committee for Excision BioTherapeutics; Inhibikase Therapeutics, Inc.; and Novartis. He serves as a consultant for Amgen Inc.; Biogen; Celgene Corporation; Dr. Reddy’s Laboratories; Encycle Therapeutics; Genentech, Inc./Roche; Mapi-Pharma; Merck & Co., Inc.; Morphic Therapeutic; Novartis; EMD Serono, Inc.; and Shire.

Dr. Cross reports she receives research support from The Conrad N. Hilton Foundation and U.S. Department of Defense. She serves on the advisory committee for EMD Serono, Inc. and Genentech, Inc./Roche. She is consultant for Biogen; Celgene Corporation; EMD Serono, Inc.; Genentech, Inc./Roche; and Novartis.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

  • Alaeddin Abukabda, MS, DMD, PhD (planning committee)
  • Jeffrey Helfand, DO (peer reviewer)
  • Mae Ochoa, RPh (peer reviewer)
  • Evan Luberger (planning committee)
  • Jan Perez (planning committee)
  • Sharon Tordoff (planning committee)


Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.


NOTE: Pharmacist CE Universal Activity Number, Enduring: JA0007185-0000-21-160-H01-P.


Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).


Right Patient, Right Treatment, Right Time: Utilizing Early, High-Efficacy Therapies to Improve Outcomes in RRMS
Event Date: 06/08/2020